Search
  • Search

    REQUEST FOR INFORMATION: Bladder Methylation Test

    HUS-yhtymä

    REQUEST FOR INFORMATION: Bladder Methylation Test

    1. Planning notice published

      Mar 3, 7:51 AMMarch 3, 2026 7:51 AM

    2. Planned competition start

      May 29, 12:00 AMMay 29, 2026 12:00 AM

    Brief

    Finland: Tenders/HUS-yhtymä/REQUEST FOR INFORMATION: Bladder Methylation Test

    Published deadline passed

    The published deadline has passed. For multi-stage competitions a later tender deadline may still apply — check the notice or portal for the current phase.

    Brief

    Laboratorie- og analyseutstyr

    HUS-yhtymä is planning the procurement of a bladder methylation test, looking for an all-in-one product based on methylation markers suitable for determining the degree of methylation of the promoter regions of several cancer genes. Suppliers can provide feedback by submitting responses via email to kilpailutus.diagnostiikka@hus.fi, including a contact person and email address for potential one-to-one market dialogue.

    About the bid

      With this request for information, HUS launches a market consultation to prepare a procurement. The aim of this prior information notice is to find suppliers operating in this field of business, get information of the solutions available in the market, and inform our plans and requirements for the forthcoming procurement. DESCRIPTION OF THE SUBJECT OF THE REQUEST FOR INFORMATION HUS Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is a SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic and follow-up genetic testing services to all patients at Helsinki University Hospital area. Diagnosis and monitoring of bladder cancer still require cystoscopy and urine cytology. Commercial non-invasive, urine-based methylation tests are available, but are not publicly available in Finland. Guidelines of European Association of Urology (EAU) recommend urinary biomarkers can be used to prolong endoscopy intervals and in equivocal cases. Our laboratory is looking for all-in-one product based on methylation markers suitable for determining the degree of methylation of the promoter regions of the several cancer genes. It is difficult to estimate number of studies per year, but should be thousands of samples. This Request for Information is released for preliminary evaluation and market research for potential solutions for methylation of the promoter region of the cancer genes and it includes a request for information regarding two different test formats: a standard test (A) and a rapid test (B). INSTRUCTIONS FOR ANSWERING Responses to this request for information must be submitted by email to kilpailutus.diagnostiikka@hus.fi no later than 17 March 2026. The subject line of the email must include: HUS 440-2025 Bladder Methylation Test. A response may be submitted for either one or both test formats. The response must include all the information requested below for the test format to which the respondent chooses to respond. The respondent is also requested to provide a contact person and an email address for any potential subsequent one-to-one market dialogue and/or additional information requests from the contracting authority. Respondents may also attach any available brochures related to the proposed products or services. A) Bladder Methylation Test - the product should be applicable to the equipment in the laboratory: - How much urine the test needs ? - Is the use of automated DNA isolation methods (for example: Maxwell/QIA Symphony) acceptable if DNA isolation is needed? - Does the kit have a CE-IVD mark (IVDR regulation requirements)? - Does the kit have a plan to obtain the CE-IVD mark (IVDR regulation requirements)? - How many methylation markers are included in the kit? - What kind of equipments does the kit require? List what. - What method is the research based on? Is it suitable for QuantStudio 5 or 6 ? - Is the result quantitative? - Is there a threshold value set by the manufacturer for a positive result? - What is the sensitivity and accuracy of the method? - How many samples can be examined with one kit? - How many samples can be made in one run? - How long does the laboratory work + analysis of one sample take? - Does the kit include a positive and negative control? - Is bisulfite conversion necessary? Does the kit include reagents for the bisulfite conversion reaction? If not, does the manufacturer have a separate putty for this. - If the kit has a CE-IVD marking, is it specified in the kit which method should be used for bisulfite conversion? - Is there an analysis software available for the kit? - Is the analysis software free of charge? - Is the software in a cloud service or can it be installed in the user's own closed operating environment? - Is the manual available electronically? - What is the price estimate for one sample? - Has the method been validated in prospective clinical drug trials? List where. - Description of the methylation test offered - Estimation of the turn-around-time - Estimation of the cost of the service (e.g., product support and training) A) Rapid Bladder Methylation Test: - What kind of equipments and kits does the test require? List what. - Does the kit have a CE-IVD mark (IVDR regulation requirements)? - Does the kit have a plan to obtain the CE-IVD mark (IVDR regulation requirements)? - How many methylation markers are included in the kit? - Is the result quantitative? - What is the sensitivity and accuracy of the method? - How many samples can be examined with one kit? - How many samples can be made in one run? - Does the kit include a positive and negative control? - How long does the laboratory work + analysis of one sample take? - Is the analysis software free of charge? - Is the software in a cloud service or can it be installed in the user's own closed operating environment? - Is the manual available electronically? - What is the price estimate for one sample? - Has the method been validated in prospective clinical drug trials? List where. - Description of the methylation test offered - Estimation of the turn-around-time - Estimation of the cost of the service (e.g., product support and training)

      Contact name
      Diagnostiikka
      Contact phone
      +358 94711
      Contact email
      kilpailutus.diagnostiikka@hus.fi
      Address
      Uutistie 5, 01770 Vantaa

    Custom Assessment Criteria

    Start a free trial to ask your own questions about the tender and get AI-generated answers.

    Award Criteria

      Found no award criteria in the contract notice.

    Qualification requirements

      Found no qualification requirements in the contract notice.

    Previous Contract Winners

    Start a free trial to see who has won similar tenders for this buyer.

    See the full notice

    Contracting authority
    HUS-yhtymä
    Title
    REQUEST FOR INFORMATION: Bladder Methylation Test
    Type
    Planning
    Main code
    33696500Laboratory reagents
    Supplemental codes
    33000000Medical equipments, pharmaceuticals and personal care products
    Location
    Helsinki-Uusimaa

    Active similar competitions

    • HUS-yhtymä

      Medisinsk og laboratorieutstyr

      REQUEST FOR INFORMATION: SPRI Beads

      HUS-yhtymä is planning the procurement of DNA size selection reagents based on paramagnetic beads, utilizing SPRI technology for selective binding and purification of DNA fragments, to be used in next-generation sequencing (NGS) library preparation. Suppliers can provide feedback and input by submitting a response via email to kilpailutus.diagnostiikka@hus.fi, addressing all requirements, providing requested information and documentation, and identifying any concerns or proposed amendments to the draft agreement.

      PlanningAug 18, 2026
      Nov 1, 2026(3 days)

    • HUS-yhtymä

      Helse- og sosial tjenesteyting

      HUS Subcontracting genetic diagnostic tests

      HUS Group needs genetic diagnostic test services to support clinical patient work and individual patient treatment decisions. These services are for various clinics within the HUS Joint Municipal Authority for Specialised Health Care, and also for ISLAB (Eastern Finland Laboratory Centre, Joint Authority Enterprise). The services are procured through a dynamic purchasing system. Suppliers must have a yearly turnover of at least EUR 500,000, a risk category of RL1-RL3, professional experience with similar genetic diagnostic test services for reference customers during the last three years, and the laboratory must have accreditation status secured for at least two years. Additionally, candidates must have experience in supplying at least 5000 genetic studies yearly for university-level or similar hospitals within the EU/EEA area. Award criteria for specific competitions will be based on overall financial affordability, which may include price and/or quality.

      Dynamic purchasing systemMar 24, 2025
      May 9, 2030(100+ days)

    • HUS-yhtymä

      Medisinsk og laboratorieutstyr

      TIETOPYYNTÖ: Entsyymi-immunologinen (EIA-) määrityskitti Helicobacter pylori -antigeenin osoittamiseen ihmisen ulosteesta

      HUS-yhtymä kartoittaa markkinoilla olevia entsyymi-immunologisia määrityskittejä ja niihin kuuluvia reagensseja sekä tarvikkeita Helicobacter pylori -antigeenin osoittamiseen ihmisen ulosteesta. Toimittajia pyydetään toimittamaan sähköpostitse tietoa saatavilla olevista tuotteista ja esitteitä; HUS voi lisäksi ehdottaa vastanneille tarkentavia markkinavuoropuheluja.

      PlanningOct 23, 2026
      Feb 23, 2027(117 days)

    • HUS-yhtymä

      Laboratorie-kits og reagenser

      Automaattinen nukleiinihappojen eristyslaite

      HUS-yhtymä suunnittelee automaattisen nukleiinihappojen eristyslaitteen hankintaa HUS Diagnostiikkakeskuksen Kliinisen mikrobiologian nukleiinihappoanalytiikkaan, sisältäen laitteen, varalaitteen tai kaksi erillistä eristysmoduulia sekä tarvittavat reagenssit ja tarvikkeet. Hankittavalla laitteella on tarkoitus eristää bakteeri-DNA:ta useista eri näytemateriaaleista, ja eristetyn tuotteen tulee olla validoitu bakteerien 16S-geenin PCR-monistamiseen Sanger-sekvensoinnilla. Toimittajia pyydetään tutustumaan liitteenä oleviin kysymyksiin ja toimittamaan vastaukset sähköpostitse osoitteeseen kilpailutus.diagnostiikka@hus.fi. bioMérieux Suomi OY:llä on todennäköisesti sopimus tällä hetkellä.

      PlanningSep 16, 2026
      Jan 16, 2027(79 days)

    • HUS-yhtymä

      Laboratorie- og analyseutstyr

      MLPA-Based CNV Testing for BRCA1/BRCA2

      HUS Group, the joint authority for Helsinki and Uusimaa, needs an MLPA (Multiplex Ligation-dependent Probe Amplification) assay for the detection of copy number variations (CNVs) in BRCA1 and BRCA2 genes, including all reagents, controls, consumables, software, licenses, and other components required for routine use and generation of reportable patient results. The contract period is 2 years, after which it continues indefinitely until terminated. The estimated annual consumption is approximately 1600 reportable patient samples, to be delivered to the HUSLAB Laboratory of Genetics in Helsinki-Uusimaa, Finland. The award criterion is the lowest total comparison price.

      CompetitionOct 7, 2026
      Nov 9, 2026(11 days)